MindWalk Holdings Corp SEC Filings

MindWalk Holdings Corp. filed a Form 6-K highlighting a press release that its President and CEO, Dr. Jennifer Bath, will join a Jones AI Day virtual panel on June 15, 2026, focused on the future of AI-driven drug discovery.

The event will examine how high-performance compute, native biological knowledge representations, and generative and agentic AI can address long-standing drug discovery challenges. MindWalk describes its HYFT® system, which powers ReefIQ™, as a biological context layer built on 25 years of wet-lab expertise, organizing 660 million biological patterns and 25 billion relationships.

Its LensAI™ platform runs on this infrastructure to support target discovery, candidate diligence, portfolio decisions, and agentic AI workflows. MindWalk notes LensAI is already used in contracted, recurring arrangements with life-sciences customers and includes extensive forward-looking statements language outlining assumptions and risks around adoption, infrastructure, competition, and regulation.

MindWalk Holdings Corp. announced the launch of ReefIQ™, a HYFT-powered biological context layer that connects fragmented drug-discovery data to AI reasoning workflows. ReefIQ links sequences, structures, assays, omics, literature, evidence, provenance, and program history into governed, queryable biological context for AI-enabled discovery.

The platform sits between client discovery data and AI models, feeding MindWalk’s LensAI™ reasoning layer and customer-selected agent models. HYFT® provides the underlying biological representation, while ReefIQ harmonizes customer data and governance, and LensAI applies retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support.

MindWalk positions ReefIQ as the foundation for future life-sciences engagements, with architecture designed for flexible integration across data governance, model access, and compute deployment. The company notes that LensAI is already used in contracted, recurring arrangements with life-sciences customers.

MindWalk Holdings Corp. announced the launch of ReefIQ™, a HYFT-powered biological context layer that connects fragmented drug-discovery data to AI reasoning workflows. ReefIQ links sequences, structures, assays, omics, literature, evidence, provenance, and program history into governed, queryable biological context for AI-enabled discovery.

The platform sits between client discovery data and AI models, feeding MindWalk’s LensAI™ reasoning layer and customer-selected agent models. HYFT® provides the underlying biological representation, while ReefIQ harmonizes customer data and governance, and LensAI applies retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support.

MindWalk positions ReefIQ as the foundation for future life-sciences engagements, with architecture designed for flexible integration across data governance, model access, and compute deployment. The company notes that LensAI is already used in contracted, recurring arrangements with life-sciences customers.

MindWalk Holdings Corp. filed a Form 6-K featuring a press release on preclinical dengue results from its HYFT® AI platform. HYFT® computationally identified a candidate pan-serotype dengue target before any animal was immunized. Immunogens built on this target elicited antibodies that bound antigens from all four dengue serotypes in two independent campaigns.

Scrambled-sequence controls did not show the same cross-serotype recognition, suggesting the response was specific to the designed immunogen. MindWalk positions this as its first public evidence of a closed prediction-to-result loop on the vaccine platform and as an asset within its broader Biointelligence Platform and Knowledge Graph, which it is applying to dengue, influenza and other multi-strain programs.

MindWalk Holdings Corp. filed a Form 6-K featuring a press release on preclinical dengue results from its HYFT® AI platform. HYFT® computationally identified a candidate pan-serotype dengue target before any animal was immunized. Immunogens built on this target elicited antibodies that bound antigens from all four dengue serotypes in two independent campaigns.

Scrambled-sequence controls did not show the same cross-serotype recognition, suggesting the response was specific to the designed immunogen. MindWalk positions this as its first public evidence of a closed prediction-to-result loop on the vaccine platform and as an asset within its broader Biointelligence Platform and Knowledge Graph, which it is applying to dengue, influenza and other multi-strain programs.

MindWalk Holdings Corp. announced the launch of its Pandemic Response Platform, a configuration of its HYFT® biological pattern system and LensAI™ platform designed for outbreak preparedness and rapid countermeasure design against RNA viruses. The platform focuses on pan-strain antigen and antibody generation by targeting structural constraints that viable RNA virus variants must preserve, rather than mutable surface proteins.

The same infrastructure has supported more than 20 molecules advanced to the clinic and is already deployed on MindWalk’s wholly owned pan-serotype Dengue and universal Influenza programs, both at in vivo proof-of-concept stage with cross-strain neutralization assays underway. The Knowledge Graph underlying HYFT encodes 660 million biological patterns and 25 billion relationships accumulated over roughly two decades, enabling LensAI to index new pathogen sequences without retraining and to prioritize candidates intended to remain relevant across future variants.

MindWalk Holdings Corp. announced the launch of its Pandemic Response Platform, a configuration of its HYFT® biological pattern system and LensAI™ platform designed for outbreak preparedness and rapid countermeasure design against RNA viruses. The platform focuses on pan-strain antigen and antibody generation by targeting structural constraints that viable RNA virus variants must preserve, rather than mutable surface proteins.

The same infrastructure has supported more than 20 molecules advanced to the clinic and is already deployed on MindWalk’s wholly owned pan-serotype Dengue and universal Influenza programs, both at in vivo proof-of-concept stage with cross-strain neutralization assays underway. The Knowledge Graph underlying HYFT encodes 660 million biological patterns and 25 billion relationships accumulated over roughly two decades, enabling LensAI to index new pathogen sequences without retraining and to prioritize candidates intended to remain relevant across future variants.

MindWalk Holdings Corp. released a report highlighting its role in creating over 20 partner-owned drug programs that originated from its antibody discovery work, with 10 currently in active Phase 1–3 clinical trials across multiple disease areas. The company explains that partners fully own and fund these clinical assets, while MindWalk’s contribution centers on discovery and candidate selection. It emphasizes its integrated model combining proprietary wet-lab antibody discovery, including camelid VHH nanobody discovery via the B cell Llama™ platform, with its HYFT® biological intelligence system and LensAI™ platform. MindWalk also notes a record of more than 400 peer-reviewed publications and patents and describes its HYFT® Knowledge Graph, which indexes hundreds of millions of biological patterns and billions of relationships to support AI-native drug discovery workflows.

MindWalk Holdings Corp. released a report highlighting its role in creating over 20 partner-owned drug programs that originated from its antibody discovery work, with 10 currently in active Phase 1–3 clinical trials across multiple disease areas. The company explains that partners fully own and fund these clinical assets, while MindWalk’s contribution centers on discovery and candidate selection. It emphasizes its integrated model combining proprietary wet-lab antibody discovery, including camelid VHH nanobody discovery via the B cell Llama™ platform, with its HYFT® biological intelligence system and LensAI™ platform. MindWalk also notes a record of more than 400 peer-reviewed publications and patents and describes its HYFT® Knowledge Graph, which indexes hundreds of millions of biological patterns and billions of relationships to support AI-native drug discovery workflows.

MindWalk Holdings Corp. filing: Ingalls & Snyder, LLC reported beneficial ownership of 2,729,122 shares of Common Stock, representing 5.8% of the class as of 12/31/2025. The Schedule 13G/A states these shares are held in client accounts with shared dispositive power.

MindWalk Holdings Corp. filing: Ingalls & Snyder, LLC reported beneficial ownership of 2,729,122 shares of Common Stock, representing 5.8% of the class as of 12/31/2025. The Schedule 13G/A states these shares are held in client accounts with shared dispositive power.

MindWalk Holdings Corp. reported recent insider activity mirrored from Canada’s SEDI system. During March 18–27, 2026, insiders Tom Lynch and Scott Areglado acquired a combined 66,500 common shares in open-market purchases, deploying $77,024 at an average price of $1.1583 per share over three trading days.

Lynch bought 40,000 shares and now holds 41,026 common shares, or 0.09% of outstanding shares, while Areglado bought 26,500 shares and now holds 26,500 common shares, or 0.06% of outstanding shares. The report also highlights previously granted restricted stock units: 225,000 RSUs to Lynch and 185,000 RSUs to Areglado, each expiring on 2029-10-29. MindWalk notes it is exempt from Section 16 reporting and is providing this update voluntarily for U.S. investors.

MindWalk Holdings Corp. furnished a Form 6-K to share insider trading data reported on Canada’s SEDI system for March 16–20, 2026. Two insiders, Dirk M.H. Van Hyfte and Ingrid M.H. Brands, bought a combined 60,000 common shares in open-market NASDAQ trades, deploying $73,238 at an average price of $1.2178 per share.

Each insider, through vehicles Charmquark EEN and Charmquark TWEE, acquired 30,000 shares, increasing their respective holdings from 1,828,365 to 1,858,365 shares, representing 3.98% of outstanding shares each. The company notes it is exempt from U.S. Section 16 filing requirements and is providing this SEDI-based information voluntarily.

MindWalk Holdings Corp. reported strong top-line growth while remaining loss-making as it pivots to a software-led AI model. Revenue reached $4.2M for the quarter and $11.4M for the nine months ended January 31, 2026, up about 52% and 45% from a year earlier, driven mainly by Canadian B-cell project work.

Quarterly gross margin was 59%, above the company’s historical 48–57% range, with quarterly gross profit of $2.5M. Operating expenses fell sharply versus the prior-year quarter that included a large asset impairment, reducing net loss to $3.9M from $21.5M. For the nine months, net loss was $10.1M, improved from $28.1M.

Cash was $14.1M as of January 31, 2026, and management believes this is sufficient to fund operations for at least one year. Results reflect the shift toward recurring, HYFT- and LensAI-driven revenue, investment in R&D and commercialization, and the divestiture of IPA Europe B.V., which generated $10.2M USD in net proceeds.

MindWalk Holdings Corp. reported strong top-line growth while remaining loss-making as it pivots to a software-led AI model. Revenue reached $4.2M for the quarter and $11.4M for the nine months ended January 31, 2026, up about 52% and 45% from a year earlier, driven mainly by Canadian B-cell project work.

Quarterly gross margin was 59%, above the company’s historical 48–57% range, with quarterly gross profit of $2.5M. Operating expenses fell sharply versus the prior-year quarter that included a large asset impairment, reducing net loss to $3.9M from $21.5M. For the nine months, net loss was $10.1M, improved from $28.1M.

Cash was $14.1M as of January 31, 2026, and management believes this is sufficient to fund operations for at least one year. Results reflect the shift toward recurring, HYFT- and LensAI-driven revenue, investment in R&D and commercialization, and the divestiture of IPA Europe B.V., which generated $10.2M USD in net proceeds.

MindWalk Holdings Corp. reported strong top-line growth for Q3 fiscal 2026 while remaining loss-making. Revenue reached $4.2 million, up 52% from $2.7 million a year earlier, marking a third consecutive quarter of year-over-year growth. US revenue doubled to $2.6 million, and gross margin for the quarter was 59%, with year-to-date gross margin improving to 58% from 53%.

The company posted a Q3 net loss from continuing operations of $3.9 million, compared with a $22.0 million loss in the prior-year quarter that included a $21.2 million impairment. For the first nine months, revenue rose to $11.4 million from $7.9 million, while the net loss from continuing operations was $11.2 million. Cash and equivalents were $14.2 million as of January 31, 2026, up from $10.8 million at the start of the period, helped by proceeds from the sale of its Europe B.V. business.

Commercially, MindWalk signed its first one-year LensAI™ platform contract with its largest enterprise AI client, creating its first contracted, recurring platform revenue stream. The company also launched its B cell Llama™ nanobody discovery platform and advanced pipeline programs in dengue, GLP-1, and influenza toward further preclinical data.

MindWalk Holdings Corp. reported strong top-line growth for Q3 fiscal 2026 while remaining loss-making. Revenue reached $4.2 million, up 52% from $2.7 million a year earlier, marking a third consecutive quarter of year-over-year growth. US revenue doubled to $2.6 million, and gross margin for the quarter was 59%, with year-to-date gross margin improving to 58% from 53%.

The company posted a Q3 net loss from continuing operations of $3.9 million, compared with a $22.0 million loss in the prior-year quarter that included a $21.2 million impairment. For the first nine months, revenue rose to $11.4 million from $7.9 million, while the net loss from continuing operations was $11.2 million. Cash and equivalents were $14.2 million as of January 31, 2026, up from $10.8 million at the start of the period, helped by proceeds from the sale of its Europe B.V. business.

Commercially, MindWalk signed its first one-year LensAI™ platform contract with its largest enterprise AI client, creating its first contracted, recurring platform revenue stream. The company also launched its B cell Llama™ nanobody discovery platform and advanced pipeline programs in dengue, GLP-1, and influenza toward further preclinical data.